Financial Report Outlook | Facing the test of exceeding expectations for eight consecutive quarters, Pfizer's Q3 reveals the effectiveness of TrumpRx investment.

According to the Securities Times app, Pfizer (PFE.US) will release its third quarter financial report before the opening of the US stock market on November 4th (Tuesday). Market expectations are for earnings per share to reach $0.64, a 39.6% year-on-year decline; revenue is expected to be $16.52 billion, a 6.7% year-on-year decrease. It is worth noting that this pharmaceutical giant has exceeded earnings expectations for eight consecutive quarters, but revenue has only surpassed market expectations in 63% of quarters.